These findings substantiate the notion that RT could transform a tumor into an ‘in situ vaccine’ (Table 1).74 Importantly, a subset of DCs, now termed DC1 are critical for crosspriming of cytotoxic T lymphocytes including those involved in tumor immunity. Here, ZDHHC4 is linked to neoplasm.